Drugs / FP-045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04522375 | Jun 2023 → Jun 2025 | Fanconi anemia | Foresee Pharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03686930 Comparator | Feb → May 2018 | — | Foresee Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-30 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease foreseepharma.com ↗ |
| 2023-09-30 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium foreseepharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04522375 ↗ |
| Action | Activate | “activator of aldehyde dehydrogenase” NCT04522375 ↗ |
| Route | Oral | “FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data.” NCT03686930 ↗ |